FindTrial
Sign In

The Impact of Perioperative Anti-inflammatory and Analgesia Measures on Tumor Recurrence in Cytoreductive Surgery

The Impact of Perioperative Anti-inflammatory and Analgesia Measures on Tumor Recurrence in Cytoreductive Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008334
Enrollment
Unknown
Registered
2016-04-21
Start date
2016-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Interventions

Group E:? receptor opiods:oxycodone+anti-inflammatory:methylprednisolone
Group C:µ receptor opiods:sulfentanyl

Sponsors

Xuan Wu Hospital of CCMU
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18~70 years; 2. American Society of Anesthesiologists (ASA) physical status I~III; 3. Patients scheduled for cytoreductive surgery.

Exclusion criteria

Exclusion criteria: 1. Significant renal impairment(creatinine>177µmol/L); Congestive heart-failure (NYHA status IV) or other severe systemic disease; 2. Cerebral vascular disease within 6 months, include cerebral hemorrhage and infraction, or over 6 months but with neurological sequelae; 3. Patients with diabetes or coronary heart disease; 4. Patients with tumor diseases except ovarian cancer; 5. Acute trauma or inflammatory disease; 6. History of drug and alcohol abuse.

Design outcomes

Primary

MeasureTime frame
Rucurrence of ovarian cancer;Progression free survival;—

Secondary

MeasureTime frame
Hospital stay;Postoperative complication rate;Syndecan-1;TNF-a;Endotoxin;C reactive protein;—

Countries

China

Contacts

Public ContactWANG TIANLONG

Xuan Wu Hospital of CCMU

w_tl5595@hotmail.com+86 13910525304

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026